Active	Status	Sponsor type	Region	Phase	Filter
32 Active 12 Inactive 44 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zhang, Wenhong
HS-10234-401, NCT06743438: Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB	Active, not recruiting	4	640	RoW	Tenofovir Amibufenamide（TMF）, HS-10234	Jiangsu Hansoh Pharmaceutical Co., Ltd.	Hepatitis B, Chronic	06/24	09/29
NCT04201808: Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides	Recruiting	4	100	RoW	Tenofovir Alafenamide 25 MG, Vemlidy	New Discovery LLC, Beijing Ditan Hospital	Hepatitis B, Chronic	09/23	09/23
NCT05279235: Efficacy and Safety of JT001 (VV116) Compared With Favipiravir	Terminated	3	290	RoW	JT001, VV116, JT001 placebo, VV116 placebo, Favipiravir, Favipiravir placebo	Shanghai Vinnerna Biosciences Co., Ltd., Sponsor GmbH	Moderate to Severe COVID-19	12/22	12/22
ZX-7101A-207, NCT06099873: Study to Assess the Safety and Efficacy of ZX-7101A in Adolescents with Influenza	Recruiting	3	360	RoW	ZX-7101A, Placebo	Nanjing Zenshine Pharmaceuticals	Respiratory Viral Infection	01/25	03/25
NCT05242042: JT001 (VV116) for the Early Treatment of COVID-19	Terminated	2/3	381	RoW	JT001, VV116, Placebo	Shanghai JunTop Biosciences Co., LTD, Sponsor GmbH	Mild to Moderate COVID-19	03/23	03/23
NCT05445934: Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)	Recruiting	2/3	1188	RoW	FB2001, DC402234, FB2001 placebo	Frontier Biotechnologies Inc.	COVID-19	11/23	12/23
B-UNITED, NCT06537414: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)	Recruiting	2	280	Europe, Canada, Japan, US, RoW	Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo	GlaxoSmithKline	Chronic Hepatitis B Virus Infection, Hepatitis B	10/27	10/27
NCT05217732: Study to Assess the Safety, Tolerability and Pharmacokinetics of ZX-7101A and the Food Effect in Healthy Volunteers	Completed	1	66	RoW	ZX-7101A, Placebo	Nanjing Zenshine Pharmaceuticals	Safety Issues, Tolerance, Pharmacokinetics, Food Effect	08/22	12/22